Group items tagged

HIV in heterosexuals is itself a major discriminatory crisis. But for men who have sex with men (MSMs) living with HIV, it is a double jeopardy. Throughout the world they are at double risk of contracting HIV and low coverage of HIV services. So, in order to prevent and control HIV we must protect and promote the human rights of the most vulnerable and typically marginalized people. It is feared that by 2020, 50% of all MSMs in the Asia Pacific region will be living with HIV.

Boston, MA -- Julio Frenk, Dean of the Harvard School of Public Health, today expressed "the continuing concern and distress of the public health community regarding the detention by Iranian authorities of Dr. Kamiar Alaei, a 2007 Masters of Science graduate of our School, and of his brother, Dr. Arash Alaei. The brothers are Iranian physicians working on the prevention and treatment of HIV/AIDS and who, in the course of their studies and work, have interacted with the international public health community."

Market Overview: Next-generation antibody therapeutics includes the use of new improvised therapeutic antibody to form innovative medicines for treating various diseases. Next-generation antibody therapeutics is developed clinically by pharmaceutical and biotechnology companies for several diseases. The Next Generation Antibody Therapeutics Market size was worth $ XX million in 2018 and is forecasted to reach $ XX million by 2026, expected to grow at a high CAGR during the forecast period 2019-2026. Market Dynamics: The Next Generation Antibody Therapeutics Market is growing due to several factors such as rising incidence of chronic diseases, increasing emergence of antibody technology, new drug discovery, large number of government initiatives, and growing research and development activities for new therapies. Rising prevalence of chronic disease such as cancer, asthma, diabetes and COPD are boosting the growth of the next generation antibody therapeutics market. For instance, according to National Cancer Institute in 2018, in United States, an estimated 1,735,350 new cases of cancer will be diagnosed and 609,640 people will die from the disease. The development of next-generation monoclonal antibodies has expanded beyond oncology into all therapeutic areas. For instance, ADCs were initially focused primarily on cancer, but Genentech has applied to infectious diseases, leading to the discovery and development of THIOMAB antibiotic conjugates (TACs) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA). The technological advancements in antibody therapeutics have led to the development of more efficient antibody therapeutics, hence, driving the growth in the next-generation antibody therapeutics market. However, stringent government regulation, high cost and time required for research and development activities are some of the factors hindering the growth for global next-generation antibody therapeutics market. Market Segmentation: Based o